Funding for this research was provided by:
Lundbeck SAS
Article History
Accepted: 19 September 2019
First Online: 4 October 2019
Compliance with ethical standards
:
: Susumu Higuchi has received personal fees, grants, and other fees from Otsuka Pharmaceutical, as wells as grants and other fees from Lundbeck Japan during the conduct of the study as well as personal fees from Nippon Shinyaku, MSD, Yoshitomi Pharmaceutical, Jansen Pharma, Eli-Lilly Japan, Mochida Pharmaceutical, and Meiji-Seika Pharma and other fees from Nippon Shinyaku, Eisai, and Meiji-Seika Pharma, outside the submitted work. Yoshiya Moriguchi is employed by Lundbeck Japan K.K. (Tokyo, Japan) and Kristin Hui Xian Tan was employed by Lundbeck Singapore Pte Ltd at the time of study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the local and institutional research committees and with the 1964 Helsinki declaration and its later amendments. Ethical approval was granted through the Ethics committee of Clinical Research Promotion Network Japan (CRPN-J).
: All patients provided written informed consent to participate in the trial.